Cargando…
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients
Antioestrogen treatment by tamoxifen is a well-established adjuvant therapy for oestrogen receptor-alpha (ERα) positive breast cancer. Despite ERα expression some tumours do not respond to tamoxifen and we therefore delineated the potential link between the cell cycle regulator and ERα co-factor, cy...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2004
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409465/ https://www.ncbi.nlm.nih.gov/pubmed/15138475 http://dx.doi.org/10.1038/sj.bjc.6601831 |